Get the latest Zynerba Pharmaceuticals Inc (ZYNE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions Zynerba's stock on track to open at lowest level since June 2016 Aug. 7, 2017 at 8:33 a.m. ET by Tomi Kilgore Zynerba's stock volume tops 600,000 shares premarket, already above full-day average.
Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets Stock analysis for Zynerba Pharmaceuticals Inc (ZYNE:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile Get the latest Zynerba Pharmaceuticals, Inc. (ZYNE) stock news and headlines to help you in your trading and investing decisions ZYNE Zynerba Pharmaceuticals — Stock Price and Discussion | Stocktwits. DOW 1.30%. S&P 500 0.01%. NASDAQ 0.37%. Trending now. Zynerba Pharmaceuticals 5.59 0.01 (0.18%) Zynerba Pharmaceuticals NASDAQ Updated Jun 18, 2021 6:43 AM. ZYNE 5.59 0.01 (0.18%) 18,613
Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a. Zynerba Pharmaceuticals (ZYNE) closed at $4.50 in the latest trading session, marking a +0.78% move from the prior day. 3 months ago - Zacks Investment Research ZYNE Stock: Why Zynerba Pharmaceutical Shares Are Soaring Today ZYNE stock is on a roll, with investors betting its transdermal therapeutic cannabidiol gel will take off soon
To date, analysts have a $7.63 target price for Zynerba stock stock. Today 200 Day Moving Average is the resistance level (4.4724 $). 50 Day Moving Average is the resistance level (4.8529 $). 202 6 brokers have issued twelve-month target prices for Zynerba Pharmaceuticals' stock. Their forecasts range from $7.25 to $26.00. On average, they expect Zynerba Pharmaceuticals' stock price to reach $13.65 in the next twelve months. This suggests a possible upside of 157.1% from the stock's current price As of 2021 June 17, Thursday current price of ZYNE stock is 5.650$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception). Zynerba Pharmaceuticals stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame
To date, analysts have a $7.63 target price for Zynerba stock stock. Today 200 Day Moving Average is the support level (4.4724 $). 50 Day Moving Average is the support level (4.8529 $). 202 Zynerba's stock forecast. According to estimates compiled by MarketBeat, analysts' consensus target price is $14.04 for Zynerba stock, which is 99.7 percent above its current price. Among the. Stock Quote (Common Stock) Exchange (US Dollar) Price: Change (%) Volume: Today's Open: Previous Close: Intraday High: Intraday Low: 52 Week High: 52 Week Low: Data as of: Data Provided by Refinitiv. Minimum 15 minutes delayed. Investor Relations. Investor Relations. IR Information; Stock Information. Stock Quote; Stock Chart; Historical Stock Lookup; Press Releases; Events & Webcasts. View live Zynerba Pharmaceuticals, Inc chart to track its stock's price action. Find market predictions, ZYNE financials and market news Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets
Zynerba Pharmaceuticals Inc. represents 41.25 million in outstanding shares, while the company has a total market value of $217.83 million with the latest information. ZYNE stock price has been found in the range of $5.13 to $5.68 Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting - 46.4% of shares voted, quorum not established to hold annual meeting - - Meeting scheduled to reconvene June 29, 2021 at 9:00 AM EDT - - Company strongly encourages stockholders holding unvoted proxies to cast their votes - DEVON, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE.
., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common. View Zynerba Pharmaceuticals' (NASDAQ:ZYNE) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. Skip to main content. S&P 500 4,247.44. DOW 34,479.60. QQQ 341.24. 2 Specialty Retail Stocks to Add to Your Shopping List. The Latest: Biden takes subtle jabs at Trump at end of G7. G-7 leaders agree on vaccines, China and taxing.
View Zynerba Pharmaceuticals, Inc. ZYNE investment & stock information. Get the latest Zynerba Pharmaceuticals, Inc. ZYNE detailed stock quotes, stock data, Real-Time ECN, charts, stats and more Zynerba Pharmaceuticals Inc. (ZYNE): The stock short term indicators say Buy today. By Noah Smith June 18, 2021 How have the shares performed? 5 Stocks Under $10 That Are Poised to Take Off Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge.
View the real-time ZYNE price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Zynerba Pharmaceuticals against related stocks people have also bought like SPPI, AGEN, CPRX, and LLNW . Follow ZYNE. 5.54-0.04 (-0.72%) Upgrade to Real-Time Regular Market . Low 2.80. 52 Week Range. High 9.00. Best deals to access real time data! Big Cap Pro. Monthly Subscription. for only. $52.04. Free trial. Small Cap Basic. Monthly Subscription. for only. $33.03. Free trial . Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex.
Zynerba Pharmaceuticals currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of Buy. A buy rating indicates that analysts believe ZYNE will outperform the market and that investors should add to their positions of Zynerba Pharmaceuticals. View the latest ratings for ZYNE The Zynerba Pharmaceuticals stock price fell by -1.97% on the last day (Friday, 18th Jun 2021) from $5.58 to $5.47. and has now fallen 3 days in a row. During the day the stock fluctuated 4.66% from a day low at $5.37 to a day high of $5.62. The price has been going up and down for this period, and there has been a 6.01% gain for the last 2 weeks. Volume has increased on the last day by 476. ZYNE Stock Summary. Zynerba Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.07% of US listed stocks. With a price/sales ratio of 1,661.62, Zynerba Pharmaceuticals Inc has a higher such ratio than 99.79% of stocks in our set. The volatility of Zynerba Pharmaceuticals Inc's share price is greater than that of 93.47% US.
. [NASDAQ: ZYNE] gained 7.58% on the last trading session, reaching $5.68 price per share at the time. The company report on May 27, 2021 that Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.. Get the hottest stocks to trade every day before the market opens 100% free Zynerba Pharmaceuticals Stock Forecast NASDAQ:ZYNE Price Target and Analyst Ratings. Most Recent Rating. Cantor Fitzgerald is very positive about ZYNE and gave it a Overweight rating on May 06, 2021. The price target was changed from $6.00 to $8.00. Last 30 Days. Historical Ratings. Date Rating Action Authority Current Price Target Price; 2021-05-06: Overweight: Target Raised by: Cantor.
Find real-time ZYNE - Zynerba Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business . had a pretty favorable run when it comes to the market performance. The 1-year high price for the company's stock is recorded $9.00 on 02/10/21, with the lowest value was $3.23 for the same time period, recorded on 01/05/21.. (ZYNE) full year performance was 14.25
Company profile page for Zynerba Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact informatio Get Zynerba Pharmaceuticals Inc (ZYNE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC
View the latest ZYNE stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of ZYNERBA PHARMACEUTICALS, INC. Zynerba Pharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Zynerba Pharmaceuticals stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Zynerba Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Zynerba Pharmaceuticals's ZYNE shares and potentially its market environment have been in a. Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) Up by almost 8% by early morning, Zynerba Pharmaceuticals is as its name suggests, a biotech penny stock. Before we get into why ZYNE stock jumped today, let's take a closer look at what the company is working on. Zynerbia focuses on transdermal cannabinoid therapies for rare and near-rare. Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know. Zacks. 06:45AM : Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel in Fragile X Syndrome. GlobeNewswire. Jan-31-20 03:45PM : Top Marijuana Stocks on the NASDAQ. Investopedia . Jan-28-20 05:45PM : Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What. .2% whereas the S&P 500 gained 19.3%. In 2018, ZYNE shares lost 77.9% whereas the S&P 500 lost 7.5%. Who Are Zynerba's Rivals? To gauge Zynerba's prospects, we must look at its competitors. Takeda Pharmaceutical (NYSE: TAK) Zynerba is targeting Tourette's Syndrome, so it'll have to deal with Takeda Pharmaceutical.
Our Pipeline - Zynerba. Advancing science. Improving connections. We focus our research and development efforts on rare (affecting fewer than 200K patients in the U.S.) and near-rare (affecting fewer than one million patients) neuropsychiatric conditions. Our lead product candidate, ZygelTM is a CBD gel currently being evaluated for Fragile X. Analysts gave the Zynerba Pharmaceuticals, Inc. (ZYNE) stock a consensus recommendation rating of Overweight, calculated at a mean rating of 2. If we narrow down to specifics, the data shows that none out of 6 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, 2 recommended ZYNE as a Hold, 4 felt it is a Buy and none rated the stock as.
Zynerba Pharmaceuticals Inc live price charts and stock performance over time. Use technical analysis tools such as candles & Fibonacci to generate different instrument comparisons Check the real-time ZYNE stock price on the NASDAQ exchange and access historical data for Zynerba Pharmaceuticals, Inc. stock. Instantly find out the Zynerba Pharmaceuticals, Inc. stock quot News Zynerba Pharmaceuticals Inc.ZYNE. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted.
Why Zynerba Pharmaceuticals Stock Is Crashing Today Investors appear to be worried about potential safety issues with its cannabinoid gel. Keith Speights (TMFFishBiz) Sep 18, 2019 at 11:50AM. Zynerba Pharmaceuticals Inc is near the top in its industry group according to InvestorsObserver.ZYNE gets an overall rating of 46. That means it scores higher than 46 percent of stocks. Zynerba Pharmaceuticals Inc gets a 88 rank in the Drug Manufacturers - Specialty & Generic industry. Drug Manufacturers - Specialty & Generic is number 142 out of 148 industries
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) stock closed at 5.28 per share at the end of the most recent trading day (a 1.15 % change compared to the prior day closing price) with a volume of 1.96M shares and market capitalization of 231.84M.Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 28. Find a variety of Zynerba Pharmaceuticals Inc statistics including live ZYNE stock quotes, market price charts, market cap, and everything you need to know to invest in ZYNE
The stock price of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is trading at over 20% today. This is why it happened. The stock price of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) — a company that focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders — is trading at over 20% today ZYNE, Zynerba Pharmaceuticals - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headline Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7% 09/18/20-7:51AM EST Zacks Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know 07/29/20-4:50PM EST Zacks. More. DEVON, Pa. , July 20, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a price of $8.00 per share, for a gross deal size of $32.5 million , before deducting underwritin Zynerba Pharmaceuticals announced that it is selling 2.8 million shares of its common stock at a price of $18.00 per share. The offering is expected to net the company slightly more than $50.
ZYNE Zynerba Pharmaceuticals Inc Additional Proxy Soliciting Materials (definitive) (defa14a) Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously. Register now to create your own custom streaming stock watchlist. NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes. All other quotes are delayed by at least 15 minutes unless. Find the latest Zynerba Pharmaceuticals, Inc. (ZYNE) stock quote, history, news and other vital information to help you with your stock trading and investing Get today's Zynerba Pharmaceuticals Inc stock price and latest ZYNE news as well as Zynerba Pharma real-time stock quotes, technical analysis, full financials and more
ZYNE stock quote, chart and news. Get Zynerba Pharmaceuticals, Inc.'s stock price today Stock split history for Zynerba Pharmaceuticals since 2021. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the Historical Prices tab for adjusted price values Promoted If you're looking to trade Zynerba Pharmaceuticals, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account
Zynerba Pharma Inc. (NASDAQ: ZYNE) stock gained by 4.68% at the last close while the ZYNE stock price falls by 1.06% during the pre-market session. Zynerba Pharmaceuticals is a pioneer of pharmaceutically developed transdermal cannabinoid treatments for neuropsychiatric conditions that are rare or Buy the stock from Zynerba Pharmaceuticals in three easy steps! Step 1 . Sign up for a eToro account. Use the following button and signup at eToro. Use an email address, choose a username, and pick a strong, secure password. The infrastructure and webpage of eToro is fast and secure, so you're personal info is safe. eToro Signup. Step 2 . Verify your identity. In order to buy Zynerba. September 6, 2020 Travis Garlick Stocks List Comments Off on Zynerba Pharmaceuticals has Further Upside. Zynerba Pharmaceuticals has Further Upside. Zynerba Pharmaceuticals, Inc. engages in the research and development of drugs. The company's clinical programs include: patch and gel for transdermal delivery and synthetic cannabinoid therapeutics. It is is headquartered in Devon, PA and was. (See Zynerba stock analysis on TipRanks) Anido added, If the results are positive, Zygel could become the first FDA approved treatment option for the significant unmet medical need that affects. Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went up by 7.58% from its latest closing price compared to the recent 1-year high of $9.00. The company's stock price has collected 17.36% of gains in the last five trading sessions. Press Release reported on 05/27/21 that Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual.
ZYNE Streaming Chart. Get instant access to a free live streaming chart of the Zynerba Pharmaceuticals Inc Stock. The chart is intuitive yet powerful, offering users multiple chart types including. Ladenburg Bullish on Zynerba (ZYNE) Stock as 'FDA Clarifies Its Views on Availability of Non-Prescription CBD' April 2, 2019, 3:52 PM EDT SHARE ON Zynerba Pharma CS stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions Zynerba Pharmaceuticals Inc is a company in the U.S. stock market and it is a holding in 8 U.S.-traded ETFs. ZYNE has around 4.1M shares in the U.S. ETF market Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for ZYNE is 42.5. Stocks with higher number of hedge fund positions relative to other stocks as well as relative to their historical range receive a higher sentiment score